Haemonetics Co.

Live Updates Live Coverage Has Ended So Close and Yet so Far 4:09 pm by Gerelyn Terzo The S&P 500 and Nasdaq Composite indices both crossed over into record territory during today’s trading session but they came off those lofty levels by the market closing. The Nasdaq Composite still closed up about 1% to 20,167.91 while the S&P 500 index finished the day 0.80% higher at 6,141.02. Big Tech Downgrade 12:55 pm by Gerelyn Terzo While Tesla stock received a ringing endorsement from Wall Street analysts today, Apple (Nasdaq: AAPL) is seeing the other side of the spectrum. JPMorgan analysts lowered their price target on the iPhone maker to $230 from $240, keeping their “overweight” rating on the stock. The analysts are worried about demand for the iPhone 17. Apple shares are lower by 0.79% today. The Nasdaq Composite is now up 0.70%. Benchmark Bullish on TSLA 11:01 am by Gerelyn Terzo Wall Street research firm Benchmark is bullish on EV leader Tesla (Nasdaq: TSLA). The firm believes TSLA stock has runway for 45% gains as a result of its competitive edge over rival robotaxi company Waymo. Benchmark lifted its price target on Tesla stock by a massive $125 to $450 per share. Tesla stock is up 0.39% today and is down 18.7% year-to-date. Wall Street Calls 10:00 am by Gerelyn Terzo Wall Street analysts are making some calls on the following stocks this morning: KeyBanc has started coverage of networking giant Cisco (Nasdaq: CSCO) with an “overweight” rating, saying the stock has plenty of runway for growth. Baird analysts are bullish on health stock Haemonetics (NYSE: HAE), beginning coverage with an “overweight” rating. UBS has reiterated its “neutral” rating on Apple (Nasdaq: APPL) stock, citing risks surrounding a potential deal with AI giant Perplexity. This article will be updated throughout the day, so check back often for more daily updates. The markets are showing off as stocks come within grasp of their latest all-time high levels. With the strikes between Israel and Iran seemingly behind, the markets have reason for optimism and they are taking it. All three of the major stock market averages are in the green out of the gate, including a 0.40% advance in the tech-laden Nasdaq Composite. The S&P 500 is eyeing its latest all-time high of 2025, which is in the ballpark of 6,147, its early 2025 intraday high level. After Nvidia (Nasdaq: NVDA) clinched a new record high of approximately $156 per share, bullish sentiment has enveloped technology stocks for the most part. On the economic front, the economy slowed at a steeper pace than originally expected in Q1 2025. U.S. GDP declined by 0.5% in Q1 compared to original estimates of a 0.2% contraction. As the data continues to flow in, the Commerce Department downwardly revised results in areas such as consumer spending and exports. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Up 121.40 (+0.37%) Nasdaq Composite: Up 87.92 (+0.40%) S&P 500: Up 21.43 (+0.39%) Market Movers AeroVironment (Nasdaq: AVAV) is gaining 9.2% today, extending its rally after posting impressive Q4 results that were powered by robust military drone demand, fueling a 40% increase in revenue. BP (NYSE: BP) is under pressure today amid reports that it is a takeover target involving industry giant Shell, rumors BP rebuffed. Micron Technology (Nasdaq: MU) is down slightly on the heels of its strong Q3 results, including better-than-expected profits and a positive outlook for the current quarter. The post Live Nasdaq Composite: Markets Rev Engines for Potential All-Time Highs appeared first on 24/7 Wall St..» Mehr auf 247wallst.com

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.» Mehr auf globenewswire.com

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE). “We look forward to collaborating with Pendopharm,.» Mehr auf businesswire.com